Donald Trump’s announcement of tariffs of up to 200% on pharmaceutical imports triggered a selloff in Indian pharma stocks. However, analysts believe the long-term impact could be limited, citing India’s manufacturing cost advantage, US-based production facilities of several drugmakers and uncertainty over how and when the tariffs will be implemented.
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.